Objective: To assess the sensitivity of a first-trimester combined screening test for fetal chromosomal abnormalities. Materials and Methods: From April 1999 to December 2002, 5,036 unselected women with singleton pregnancies underwent a first-trimester combined test (nuchal translucency thickness, pregnancy-associated plasma protein-A, and free β-human chorionic gonadotropin) screening for Down syndrome. They included 298 (5.9%) women aged 35 years or older and 4,738 (94.1%) women aged below 35 years. A positive result was defined as an estimated Down syndrome risk of greater than 1/270. Results: Twenty-five (0.50%) chromosomal abnormalities were identified, with a false-positive rate of 7.1% (333/4,717) in women younger than 35 years and a false-positive rate of 17.3% (51/294) in women of advanced maternal age. The 25 chromosomal abnormalities included trisomy 21 in six fetuses, trisomy 18 and Turner's syndrome in four fetuses each, Klinefelter's syndrome, a marker chromosome and pseudohermaphroditism in one fetus each, and structural rearrangements in eight, including four with balanced translocations. One fetus with trisomy 18 was not discovered at screening, but a fetal ventricular septal defect was found on ultrasound at 30 weeks' gestation. The detection rate for fetal chromosomal abnormalities was 95.2% (20/21). If a cutoff of 1 in 200 was used, the false-positive rate would be 5.6% with the same detection rate, whereas the test still yielded a detection rate of 90.5% (19/21) with a 5% false-positive rate. In 83.3% of cases with trisomy 21 and 5.7% of normal pregnancies, fetal nuchal translucency thickness measurement was above the 95 th percentile, whereas in 0.7% of the study population and in 24% of those with fetal chromosomal abnormalities, the fetal nuchal translucency thickness was at least 3 mm.
Introduction
Down syndrome is the most commonly encountered chromosomal abnormality in newborns, with an inci-dence of 1 in 800 live births. In addition to decreased mentality, about half of cases have associated congenital heart disease. Down syndrome, therefore, has a substantial socioeconomic impact. A first-trimester combined test at 10 to 13 weeks' gestation is effective in detecting Down syndrome [1] [2] [3] [4] [5] [6] [7] [8] [9] . The test consists of measurements of sonographic fetal nuchal translucency (NT) thickness, and serum levels of pregnancy-associated plasma protein-A (PAPP-A) and free β-human chorionic gonadotropin (fβ-hCG). At a 5% false-positive rate, this test can detect Down syndrome in an additional 15% to 20% of cases compared with second-trimester biochemical screening [9] [10] [11] [12] .
The combined test for Down syndrome first-trimester screening has been offered as an option to pregnant women at Cathay General Hospital since April 1999. This study analyzed the usefulness of the technique in detecting fetal chromosomal abnormalities.
Materials and Methods
From April 1999 to December 2002, a total of 5,036 unselected women with singleton pregnancies elected to have the combined test. The test involves measuring sonographic fetal NT thickness and maternal serum levels of fβ-hCG and PAPP-A at 10 to 13 weeks of gestation. Fetal NT thickness was measured according to the criteria of the Fetal Medicine Foundation in the UK [13] . Maternal serum levels of fβ-hCG and PAPP-A were determined within 1 week by microtiter-plate enzymelinked immunosorbent assay (ELISA) according to the manufacturer's protocol (Free β-hCG PNS EIA Kit and PAPP-A EIA Kit, Genemed Biotechnologies, South San Francisco, CA, USA). NT thickness, PAPP-A, and fβ-hCG values were divided by their respective day-specific medians to determine the multiples of the median (MoM) for each marker. Down syndrome risk was calculated using Alpha Software (Logical Medical Systems, London, UK) based on a multivariate Gaussian distribution as described by Wald et al [14] . A positive result was defined as an estimated Down syndrome risk of more than 1/270. All chromosome analyses were carried out in the Cytogenetics Laboratory of Cathay General Hospital. For cultured chorionic villus tissue and amniocytes, four primary cultures were performed using an in situ method with CHANG MEDIUM ® BMC (Irvine Scientific, Santa Ana, CA, USA). Microscopic analysis of Giemsa-stained chromosome banding used the rules for metaphase selection and colony definition as defined by Moertel et al [15] .
Results
Among the 5,036 women, 298 (5.9%) were aged 35 years or older, and 4,738 (94.1%) were aged below 35 years. The median maternal age was 30.0 years, median maternal weight was 53.5 kg, and median gestational age at screening was 83 days. Table 1 shows the median values of NT thickness, PAPP-A, and fβ-hCG at 10 to 13 weeks of gestation. The median NT thickness was 1.0 mm, median PAPP-A was 3.5 mIU/mL, and median fβ-hCG was 50.0 mIU/mL. There were 406 positive-screen pregnancies which occurred in 7.5% (353/4,738) of women younger than 35 years and 17.8% (53/298) of women of advanced maternal age. Fetal NT thickness was above the 95 th percentile in 83.3% of cases with trisomy 21 and in 5.7% of normal pregnancies, whereas it was at least 3 mm in 0.7% of all pregnancies and in 24% of those with fetal chromosomal abnormalities.
Fetal karyotyping results were available for 309 (76%) of the 406 positive screening results. The other women were lost to follow-up, and no information regarding the outcome of their pregnancies was available; all pregnancies whose outcomes were unknown were assumed to be normal. Seven women underwent chorionic villus sampling in the first trimester, while the remaining 302 women underwent amniocentesis in the second trimester. Twenty-five chromosomal abnormalities were identified, including trisomy 21 in six fetuses, trisomy 18 in four, Turner's syndrome in four, Klinefelter's syndrome in one, a marker chromosome in one, pseudohermaphroditism in one, and structural rearrangements in eight, including four with balanced translocations. One fetus with trisomy 18 was not discovered at screening, but a ventricular septal defect was found by ultrasonography at 30 weeks' gestation.
Detailed screening results for the 25 cases with chromosomal abnormalities are shown in Table 2 . A combination of a low PAPP-A level, a high fβ-hCG level, and increased NT thickness was noted in cases of trisomy 21 and monosomy X, whereas low levels of both PAPP-A and fβ-hCG were observed in cases of trisomy 18. Table 3 shows the detection and false-positive rates for fetal chromosomal abnormalities at different cutoff points. The same detection rate of 95.2% was achieved when the false-positive rate was lowered from 7.1% to 5.6%, which suggests that it would be reasonable to change the risk cutoff from the present 1 in 270 to 1 in 200. At a fixed 5% false-positive rate, the detection rate of the combined test in other studies ranged from 80% to 91% (Table 4 ) [1, [3] [4] [5] 7, 9] . Table 5 illustrates the screening performance of the combined test for fetal chromosomal abnormalities. The overall detection rate was 88.0%, with a false-positive rate of 7.7%.
Discussion
In this study, we demonstrated that in women younger than 35 years, the detection rate of fetal chromosomal abnormalities using the first-trimester combined test was 95.2% (at a risk cutoff of 1:270), with a false-positive rate of 7.1%. Even with a fixed 5% false-positive rate, the test still yielded a detection rate of 90.7% (at a risk cutoff of 1:140). As shown in Table 4 , these results are in accordance with previous studies, which reported a detection rate in the range of 80% to 91% with a 5% false-positive rate. In addition to its higher detection rate, the combined test has also been shown to be more sophisticated and cost-effective than other secondtrimester screening protocols [16] [17] [18] . However, in Taiwan, second-trimester maternal serum screening based on the combination of maternal age, α-fetoprotein, and fβ-hCG remains the most widely used Down syndrome screening protocol. This yields a detection rate of only 56% to 70% for a false-positive rate of 5% [9] [10] [11] [12] 19] . Therefore, we encourage tertiary centers in Taiwan to implement the combined test as part of the clinical Down syndrome screening protocol. The effectiveness of the combined test heavily depends on the accuracy of the sonographic measurement of fetal NT thickness. Standardization and quality control of fetal ultrasound NT examinations should therefore be emphasized [7] . Accurate measurement of NT thickness should be undertaken by fully qualified, well-trained sonographers who strictly follow the guidelines of the Fetal Medicine Foundation [13] . In this study, we found that in 83.3% of trisomy 21 cases and 5.7% of normal pregnancies, the fetal NT thickness measured was above the 95 th percentile of the normal range. These results are similar to the rates of 73.7% and 4.8%, respectively, reported by von Kaisenberg et al [8] .
Thus, ultrasonographic measurement of first-trimester NT thickness is feasible and useful in identifying Down syndrome. This screening method also identified 24% (6/25) of the fetal chromosomal abnormalities based on the finding of an NT thickness of at least 3 mm. However, fetal NT thickness alone is not an efficient screening marker for Down syndrome in the first trimester, because in order to achieve a detection rate of 85%, the false-positive rate would be as high as 21.1%. When combined with PAPP-A and fβ-hCG, the falsepositive rate was only 6% with the same detection rate of 85% [12] . Deviations from the medians of the screening markers have been associated with adverse pregnancy outcomes [20] [21] [22] [23] . Increased NT thickness is not only associated with congenital heart defects, chromosomal abnormalities, and fetal loss, but also with gestational hypertension and pre-eclampsia [22] . Low serum PAPP-A in the first trimester is also associated with fetal growth retardation, gestational hypertension, preterm delivery, and spontaneous miscarriage [23] . Therefore, in addition to detecting fetal aneuploidies, the combined test can identify women at increased risk of adverse pregnancy outcomes.
Recent reports have indicated that the integrated test will probably be the test of choice for high- performance Down syndrome screening. The Serum, Urine and Ultrasound Screening Study showed that the integrated test, which includes NT thickness and five serum markers, yielded an 85% detection rate at a falsepositive rate of 1.2%, and a 93% detection rate at a falsepositive rate of 4.5% [12] . In women of advanced maternal age, the current standard of care is to offer an invasive prenatal diagnosis with amniocentesis or chorionic villus sampling. In this study, the detection rate in women of advanced maternal age was only 50% at a false-positive rate of 17.3%. We would not recommend the first-trimester combined test for women of advanced age; instead, the integrated test might be a better option. However, further study is required to address this issue so that the number of amniocentesis-and unnecessary procedure-related fetal losses can be reduced.
In conclusion, this study demonstrates that the combined test is an effective Down syndrome screening protocol in the first trimester. Furthermore, the sonographic measurement of fetal NT thickness at 10 to 13 weeks of gestation is a useful tool for the early diagnosis of fetal structural anomalies.
